The latest price target for Biogen (NASDAQ:BIIB) was reported by BMO Capital on December 20, 2024. The analyst firm set a price target for $164.00 expecting BIIB to rise to within 12 months (a possible 11.56% upside). 77 analyst firms have reported ratings in the last year.

The latest analyst rating for Biogen (NASDAQ:BIIB) was provided by BMO Capital, and Biogen downgraded their market perform rating.

The last upgrade for Biogen Inc happened on December 7, 2023 when Raymond James raised their price target to $283. Raymond James previously had a market perform for Biogen Inc.

The last downgrade for Biogen Inc happened on December 20, 2024 when BMO Capital changed their price target from $230 to $164 for Biogen Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biogen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biogen was filed on December 20, 2024 so you should expect the next rating to be made available sometime around December 20, 2025.

While ratings are subjective and will change, the latest Biogen (BIIB) rating was a downgraded with a price target of $230.00 to $164.00. The current price Biogen (BIIB) is trading at is $147.00, which is out of the analyst’s predicted range.